AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Steroids-Based Screening for Primary Aldosteronism

Recruitingn/aAges 18 Years - 75 YearsAllQifu Li
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This prospective, single-center observational study aims to evaluate whether a steroid-based screening method can more accurately identify Primary Aldosteronism (PA) in hypertensive patients who remain on their usual antihypertensive medications, compared with the conventional aldosterone-to-renin ratio (ARR). PA is a common, potentially curable subtype of secondary hypertension that carries increased cardiovascular risk when undiagnosed or untreated. However, current screening protocols recommend "medication washout" or switching to minimally interfering drugs, which may pose safety concerns and add complexity. In this study, approximately 406 participants (ages 18-75) with diagnosed hypertension and on at least one interfering antihypertensive drug (such as ACE inhibitors, ARBs, beta-blockers, diuretics, or calcium channel blockers) will be enrolled at the Department of Endocrinology,

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Aged 18-75 years, with no sex restriction. 2. Diagnosed with hypertension, defined as a systolic blood pressure โ‰ฅ140 mmHg and/or a diastolic blood pressure โ‰ฅ90 mmHg measured on at least two different days. 3. Currently receiving at least one antihypertensive medication that interferes with aldosterone or renin (ACEI/ARB, ฮฒ-blockers, dihydropyridine CCBs, or diuretics including MRA) for โ‰ฅ4 consecutive weeks. 4. Fully informed about the study procedures and risks, and willing to participate by signing a written informed consent form. Exclusion Criteria: 1. Confirmed secondary hypertension of other etiologies (e.g., renovascular hypertension, renal artery stenosis, reninoma, pheochromocytoma, Cushing's syndrome, Liddle syndrome), excluding obstructive sleep apnea. 2. Severe cardiac, hepatic, or renal impairment or serious infections, including but not limited to New York Heart Association (NYHA) Class III-IV heart failure, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2.5 times the upper limit of normal, estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 mยฒ, or severe infections (e.g., diabetic foot, sepsis, pneumonia, refractory infections). 3. History of major cardiovascular or cerebrovascular events within the past 3 months. 4. Pregnant or breastfeeding women. 5. Currently using medications (other than the listed antihypertensives) that may affect aldosterone or renin secretion, including but not limited to sex hormones (e.g., oral contraceptives, estrogen replacement therapy), glucocorticoids (e.g., prednisone, dexamethasone), nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or antipsychotics (e.g., chlorpromazine, olanzapine). 6. Individuals lacking or having restricted capacity for independent decision-making or action. 7. History of psychiatric disorders. 8. Poor compliance likely to compromise study completion.
๐Ÿ’Š

What it tests

  • Steroid-Based Screening (LC-MS/MS)
๐Ÿ“

Where

1 site
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy